title: Reduced in vivo ocular surface toxicity with polyquad-preserved travoprost versus benzalkonium-preserved travoprost or latanoprost ophthalmic solutions.
abstract: The study used a validated acute in vivo model to compare a new formulation of travoprost 0.004% ophthalmic solution(travoprost PQ), preserved with polyquaternium-1 (PQ), with commercially available formulations of benzalkonium-chloride(BAK)-preserved travoprost 0.004% ophthalmic solution(travoprost BAK) and BAK-preserved latanoprost 0.005%ophthalmic solution (latanoprost BAK). Adult male New Zealand albino rabbits (n = 36) were randomly divided into 6 groups. Phosphate-buffered saline (PBS), 0.001% PQ, 0.015% BAK, travoprost PQ, travoprost BAK or latanoprost BAK were applied onto rabbit eyes as 1 drop, for 15 times at 5-min intervals.The ocular surface reactions were investigated at hour 4 and day 1 using slitlamp examination; in vivo confocal microscopy (IVCM) for cornea, limbus and conjunctiva/conjunctiva-associated lymphoid tissue, conjunctival impression cytology and standard immunohistology in cryosections for detecting CD45+ infiltrating cells and MUC-5AC-labeled cells. PBS, PQ and travoprost PQ did not induce obvious irritation by clinical observation, changes in microstructures of the whole ocular surface as measured by IVCM analysis,inflammatory infiltration or cell damage as measured by impression cytology, altered levels of goblet cell counts or numerous CD45+ cells in the cornea. In contrast, all BAK-containing products induced diffuse conjunctival hyperemia and chemosis, abnormal changes in the ocular surface microstructure,significant total ocular surface toxicity scores,damaged epithelial cells, inflammatory cell infiltration and decreased goblet cell density. Travoprost PQ did not elicitocular surface toxicity when administered to rabbit eyes.These results suggest a greater safety advantage for the ocular surface of patients receiving chronic glaucoma treatment with PQ-preserved drugs.
authors.affiliation: INSERM, U968, France.
authors.forename: Hong
authors.initials: H
authors.lastname: Liang
authors.forename: Françoise
authors.initials: F
authors.lastname: Brignole-Baudouin
authors.forename: Luisa
authors.initials: L
authors.lastname: Riancho
authors.forename: Christophe
authors.initials: C
authors.lastname: Baudouin
mesh_terms: D000818:Animals; D000959:Antihypertensive Agents / Q000633:toxicity*; D001548:Benzalkonium Compounds / Q000633:toxicity*; D003008:Cloprostenol / Q000031:analogs & derivatives / Q000633:toxicity; D003228:Conjunctiva / Q000187:drug effects* / Q000378:metabolism; D003315:Cornea / Q000187:drug effects* / Q000378:metabolism; D020397:Goblet Cells / Q000187:drug effects / Q000473:pathology; D000077338:Latanoprost; D017493:Leukocyte Common Antigens / Q000378:metabolism; D008297:Male; D018613:Microscopy, Confocal; D055271:Mucin 5AC / Q000378:metabolism; D009883:Ophthalmic Solutions; D011108:Polymers / Q000633:toxicity*; D011310:Preservatives, Pharmaceutical / Q000633:toxicity*; D011461:Prostaglandins F, Synthetic / Q000633:toxicity; D011817:Rabbits; D000069557:Travoprost
chemical_list: D000959:Antihypertensive Agents; D001548:Benzalkonium Compounds; D055271:Mucin 5AC; D009883:Ophthalmic Solutions; D011108:Polymers; D011310:Preservatives, Pharmaceutical; D011461:Prostaglandins F, Synthetic; D003008:Cloprostenol; D000077338:Latanoprost; C058655:polyquaternium 1; D017493:Leukocyte Common Antigens; D000069557:Travoprost